OSSD Share Price Performance
SEK 5.99
-6.43 (-51.77%)
53.0% undervalued intrinsic discount
SEK 12.75
Fair Value
Price SEK 5.99
AnalystConsensusTarget SEK 12.75
AnalystHighTarget SEK 17.50
AnalystLowTarget SEK 13.50
Fair ValueSEK 12.75
Share Pricen/a
OssDsign AB (publ) Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
OSSD Community Narratives
AN
Fair Value SEK 12.75 53.0% undervalued intrinsic discount
Pure Play Orthobiologics Will Expand US Healthcare Access
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value SEK 17.5 65.8% undervalued intrinsic discount
U.S. Spine Market Penetration And New Orthopedic Indications Will Drive Exceptional Future Upside
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value SEK 13.5 55.6% undervalued intrinsic discount
Rising US Healthcare Cost Controls Will Squeeze Orthobiologics Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Pure Play Orthobiologics Will Expand US Healthcare Access
Key Takeaways Strategic shift to orthobiologics boosts growth and operational efficiency, enhancing future revenue and sustaining high net margins. U.S. market expansion and distinctive product benefits position OssDsign for significant market share and increased adoption.Read more
41
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
SEK 12.75
53.0% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Profit Margin
5.01%
Future PE
112.56x
Price in 2029
SEK 15.07
Rising US Healthcare Cost Controls Will Squeeze Orthobiologics Margins
Key Takeaways Intensifying pricing pressures and consolidated buyer power threaten margins and profitability, as healthcare cost controls and hospital alliances focus on affordability over innovation. High operating expenses from R&D and limited product diversification expose the company to disruptive competition, slow commercial progress, and volatile earnings.Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
SEK 13.5
55.6% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Profit Margin
0.57%
Future PE
974.33x
Price in 2029
SEK 15.91
U.S. Spine Market Penetration And New Orthopedic Indications Will Drive Exceptional Future Upside
Catalysts About OssDsign OssDsign develops advanced nanosynthetic bone graft solutions to improve bone regeneration in spine and orthopedic surgery. What are the underlying business or industry changes driving this perspective?Read more
4
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
SEK 17.5
65.8% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Profit Margin
8.07%
Future PE
88.36x
Price in 2028
SEK 20.67
Trending Discussion
Recently Updated Narratives
AN
OSSD: New US-Focused Leadership Will Support Long Term Margin Expansion
Fair Value: SEK 12.75 53.0% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
OSSD: New US Based Leadership Will Drive Future Orthobiologics Expansion
Fair Value: SEK 13.5 55.6% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
U.S. Spine Market Penetration And New Orthopedic Indications Will Drive Exceptional Future Upside
Fair Value: SEK 17.5 65.8% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
OssDsign AB (publ) Key Details
About OSSD
- Founded
- 2011
- Employees
- 34
- CEO
- WebsiteView website
OssDsign AB (publ) designs, manufactures, and sells implants and material technology for bone regeneration in Sweden, Germany, the United States, the United Kingdom, rest of Europe, and internationally. It offers OssDsign Catalyst, a nanosynthetic bone graft for dual bone formation pathways through fusion mass. The company was founded in 2011 and is headquartered in Uppsala, Sweden.
